Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002453 (amenorrhea)
 6,245 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In 15 women with either isolated amenorrhea or amenorrhea associated to galactorrhea the basal levels of PRL allowed a clear differentiation into three groups. The first group (n = 3) had normal PRL levels (x +/- SD, 8.0 +/- 4.8 ng/ml), the second group (n = 4) had moderately elevated PRL (25.6 +/- 6.5 ng/ml), and the third group (n = 8) had very high PRL (176.0 +/- 76.1 ng/ml). All the patients in the third group had a pituitary adenoma. In the three groups the basal levels of FSH and LH and their response to GnRH were measured with the purpose of uncovering possible relationships between these results and the levels of PRL, and the tumoral or non-tumoral origin of the hyperprolactinemia when it was present. No statistically significant differences were found amongst the three groups. The results suggest that hyperprolactinemia has no influence upon gonadotrophin release or the endogenous release of GnRH. The measurement of plasma gonadotrophins and their response to GnRH appears to be of no clinical value for the differential diagnosis of the hyperprolactinemias.
 ...
PMID:[Variations of the plasma levels of gonadotrophins (FSH and LH) and of its response to stimulation with gonadotrophin releasing hormone (GnRH) with different plasma levels of prolactin (PRL) in women with the syndrome of galactorrhea-amenorrhea (author's transl)]. 678 94

Fourteen young women with normal menses participated in an endurance running program to investigate the effects of physical training on menstrual function, plasma PRL, and body composition. Body composition, measured by hydrostatic weighing, and PRL (basal and TRH-stimulated ) were determined initially and after each subject had increased her weekly mileage by 30 miles (delta 30) and 50 miles (delta 50). Mean (+/- SEM) total body weight did not change, but the subjects became significantly leaner (relative fat, 25.5 +/- 1.3% at baseline vs. 22.4 +/- 0.9% at delta 50; P less than 0.02). Thirteen women developed menstrual changes (mainly oligomenorrhea), but not amenorrhea. Mean (+/- SEM) unstimulated PRL levels were 16.8 +/- 3.1%, 16.9 +/- 2.4, and 11.5 +/- 2.1 ng/ml at baseline, delta 30, and delta 50, respectively (P less than 0.03 at delta 50 compared to baseline and delta 30). Mean ( +/- SEM) integrated TRH-stimulated PRL responses increased from 5002 +/- 462 ng/ml.min at baseline to 5748 +/- 609 mg/ml.min at delta 30 and 6535 +/- 552 ng/ml.min at delta 50, and were significantly different from one another (F = 4.01; P less than 0.04). Endurance training, without total body weight loss or extreme leanness, results in frequent menstrual dysfunction. Other authors have shown that young female athletes have an increased PRL response to acute exercise compared to nonathletes. One mechanism responsible for menstrual dysfunction in endurance-trained women may be frequent and exaggerated PRL responses to exercise and other stimuli.
 ...
PMID:Prolactin responses, menstrual cycles, and body composition of women runners. 680 Oct 69

Six patients with amenorrhea, five of whom had galactorrhea and elevated PRL levels, were evaluated on a metabolic ward. All had normal sella tomograms, normal thyroid functions, and routine laboratory evaluations. None of the patients had taken any medication in the previous 6 months. On alternate days, five patients received 500 microgram of TRH iv with the measurement of PRL, TSH, FSh, LH, and hGH; 500 mg L-dopa orally with the measurement of PRL, FSH, and LH; a bolus infusion of 300 mg pyridoxine (B6) with measurement of PRL, hGH, TSH, FSH, and LH; and 25 mg chlorpromazine (CPZ) im with the measurement of PRL, LH, and FSH. The patients were then discharged on 600 mg oral pyridoxine/day and were readmitted for a repeat of the complete protocol 21 days later. The patients were continued on 600 mg oral pyridoxine for 3-4 months with monthly evaluations of serum PRL, LH, and FSH levels. These evaluations continued for 3 months after discontinuing pyridoxine. There was no demonstrable change in serum PRL after acute or chronic B6 therapy, mor was there a significant change in the response of PRL to CPZ, L-dopa, or TRH. The mean basal PRL was 97.5 +/- 9.7 ng/ml and after 3-4 months of oral pyridoxine was 97.1 +/- 14.8. In addition, there was no significant change in LH or FSH levels in response to acute or chronic B6, TRH, L-dopa, or CPZ. Neither acute B6 infusion nor chronic B6 therapy had any effect on TSH or the TSH response to TRH. Finally, acute B6 infusion had no effect on hGH levels and there were no paradoxical hGH responses to TRH. Two patients began having regular menses while on chronic pyridoxine. Their hormonal responses did not differ from those of the group, however.
 ...
PMID:The effects of pyridoxine on pituitary hormone secretion in amenorrhea-galactorrhea syndromes. 680 Oct 73

Several investigators have reported that CB-154 induces ovulation in patients with normoprolactinemic anovulation as well as those with hyperprolactinemic amenorrhea. In the present research, the ovulation-inducing effects of CB-154 were studied in normoprolactinemic subjects with special reference to the feedback effect of estradiol on LH release. Thirty female subjects aged 20 approximately 32 years with ovulatory disturbances were studied. Basal serum PRL, LH and FSH were determined by radioimmunoassay, and both hyperprolactinemic and hypergonadotropic anovulatory patients were excluded. A 2mg dose of estradiol benzoate was administered intramuscularly to each subject and 8ml samples of venous blood were taken at 0, 6, 24, 30, 48, 54, 72, 78 hr. The subjects under study were divided into two groups, A and B, according to the effect the estradiol benzoate had an LH release. Group A subjects (nine in all) failed to show any positive feedback release of LH in response to the estradiol benzoate. Group B subjects (twenty-one in all) showed a more than twofold increase in circulating LH as compared with the initial serum LH value, and this was taken as an indication of positive feedback release. All the subjects in group B were given clomiphene (50 approximately 100mg daily for five days). The clomiphene therapy was effective in eleven subjects, and four became pregnant (three in the first or second cycle of treatment and one in the third). The therapy was ineffective in the remaining six subjects, four of whom were diagnosed as suffering from polycystic ovary syndrome. Clomiphene was judged to be effective when the subjects undergoing therapy with this drug ovulated during three successive treatment cycles, and ineffective when the subjects did not fulfill this criterion (criterion for effectiveness of clomiphene). With the exception of four cases of polycystic ovary syndrome and three pregnancies which occurred in the first or second cycle, the rate of effectiveness of clomiphene in group B was 12 out of 14. It was concluded from these results that clomiphene was effective in group B subjects except in cases of polycystic ovary syndrome. Treatment with clomiphene alone was effective in none of the seven subjects in group A. However, administration of CB-154 for several weeks prior to and during the clomiphene treatment cycle (combined therapy of CB-154 and clomiphene) led to remarkably improved ovulation rates in five subjects in group A. Four patients in group A were selected, and given estradiol benzoate prior to (control) and during (study) CB-154 administration. In each case administration of CB-154 elicited marked positive feedback release of LH as compared with the control period, that is to say, CB-154 transformed group A patients into group B patients. This effect of CB-154 may explain why therapy combining CB-154 and clomiphene improved ovulation rates in group A...
 ...
PMID:[The ovulation-inducing effect of CB-154 on normoprolactinemic anovulatory subjects (author's transl)]. 680 83

Endogenous opiates are involved in the control of pituitary gonadotrophin and PRL secretion, and possibly of food intake. Both hyperprolactinaemia and weight loss (especially in anorexia nervosa) are frequently associated with amenorrhoea and an absence of gonadotrophin pulsatility. Since it has been suggested that increased endogenous opiate tone may operate in both conditions, we infused high-doses of naloxone into twelve patients with amenorrhoea of whom five had hyperprolactinaemia and seven had weight-loss related amenorrhoea. Eleven of the twelve patients had low levels of oestradiol (less than 50 pmol/l). Naloxone induced a marked rise in both LH and FSH levels in all of the five hyperprolactinaemic patients. In contrast, the patients with weight-loss amenorrhoea responded to naloxone with only a small or no rise in gonadotrophins. There was no consistent change in PRL in either group of patients. It is concluded that in hyperprolactinaemia, but not weight-loss amenorrhoea, there is an important endogenous opiate-mediated tonic inhibition of secretion of hypothalamic gonadotrophin releasing hormone.
 ...
PMID:Opiate mediation of amenorrhoea in hyperprolactinaemia and in weight-loss related amenorrhoea. 681 95

5 Amenorrhea hyperprolactinemic women in previous intermittent treatment with bromocryptine, received bromocryptine for three periods of 5, 4, 3 days; each treatment phase was followed by a ten days suspension. During treatment and during suspension FSH, LH, PRL and E2 were tested. There was no significative variation of FSH and LH; PRL lowered during treatment and reached basal values during suspension. Ovarian response (E2) varies with PRL levels. There was a statistically significative negative correlation between PRL and 17-beta-E2.
 ...
PMID:PRL action on E2 ovarian secretion. 681 97

84 patients with elevated serum PRL levels, ranging from 25 to 253 ng/ml, were treated with an antiserotonin agent, metergoline, at the dose of 12 mg/day for 90 days. The clinical complaint was of amenorrhea in 70 cases (plus galactorrhea in 44 cases) and of anovulation in 14 cases (plus galactorrhea in 6 cases). Hyperprolactinemia was due to a pituitary adenoma in 18 cases; in 53 cases it was of unknown origin, while in 7 cases it followed treatment with neuroleptics or with oral contraceptives and in 6 cases it followed a puerperium. In patients with amenorrhea, metergoline induced the appearance of menses in 61 cases (94%), and of ovulation in 46 cases (82%). In 13 of the 14 patients with anovulation, ovulation was restored. Galactorrhea disappeared in 40 out of 50 patients. Metergoline normalized serum PRL levels (less than 20 ng/ml) in 46 cases and significantly reduced serum PRL levels in all but 3 of the remaining patients. In spite of suggested nonhormonal contraceptive measures, 14 patients became pregnant; 2 had abortions and the remaining 12 patients completed by vaginal delivery, uneventful pregnancies. These results indicate metergoline as a safe and effective drug in the management of hyperprolactinemic amenorrhea and anovulation. 49 patients were followed for 2 additional months, receiving no treatment (24 cases) or metergoline at a reduced daily dosage (8 mg/day, 25 cases). Within 60 days, 60% of the first group had relapse of the clinical condition and a rebound elevation of serum PRL levels while only 20% of the second group experienced relapse of amenorrhea and rebound elevation of serum PRL levels (p less than 0.01).
 ...
PMID:Metergoline in the management of hyperprolactinemic amenorrhea and anovulation. 703 5

We report three patients with craniopharyngiomas who had galactorrhea, oligo/amenorrhea, and abnormal sellar tomograms, clinically suggesting the presence of a prolactinoma. One patient had an intrasellar craniopharyngioma (Rathke's cleft cyst) diagosed during surgical exploration of the pituitary fossa for removal of a suspected prolactinoma, and two had suprasellar caraniopharyngiomas whose presence was suspected on the basis of computed tomography. This finding emphasizes the importance of computed tomography in the evaluation of patients with the clinical presentation of a prolactinoma. In two patients, PRL levels were elevated before surgery and remained elevated after removal of the craniopharyngioma. In the third case, an initially normal serum PRL level became elevated after removal of the tumor.
 ...
PMID:Galactorrhea, oligo/amenorrhea, and hyperprolactinemia in patients with craniopharyngiomas. 719 31

Sixty-seven women who underwent transsphenoidal resection of PRL-secreting pituitary adenomas between 1976 and 1979 were separated into categories according to the manner of their clinical presentation. Forty-one had oral contraceptive-related onset of amenorrhea-galactorrhea, 5 had pregnancy-related onset of amenorrhea-galactorrhea, 5 had primary amenorrhea, and 16 had the spontaneous onset of amenorrhea-galactorrhea unrelated to estrogen use. Surgical success, defined as the resumption of regular menses and normalization of serum PRL concentration, was achieved in 54% of those with estrogen-related onset of amenorrhea-galactorrhea compared with 19% in the other group. The analysis of multiple preoperative features, including clinical classification, age, preoperative PRL concentration, and duration of amenorrhea-galactorrhea by logistic regression, demonstrated that the clinical classification was the most important factor in predicting the outcome of transsphenoidal surgery. It should be a prime consideration in the selection of therapy for PRL-secreting adenomas.
 ...
PMID:Predictors of the outcome of transsphenoidal surgery for prolactin-secreting pituitary adenomas. 719 86

Omitting hormonal variations caused by other drugs already objects of research, the behaviour pattern of GH, PRL, TSH, following acute administration of cimetidine, nomifensine, domperidone has been considered in normal subjects, in patients with pituitary non-secreting and PRL-secreting adenomas and in patients with amenorrhea-galactorrhea syndrome without evidence of adenoma. The results confirm the influence which drugs employed in the therapy of non-endocrine diseases provide a way to alter the functions of the hypothalamus, sometimes relatively specifically, and the secretion of pituitary hormones provides us with a possibility of analyzing the CNS output.
 ...
PMID:Drug-induced alterations of the hypothalamus-hypophysis axis. 723 53


<< Previous 1 2 3 4 5 6 7 8 9 10